Biological E will produce J&J’s vaccine at its vaccine production facilities and sell them both in India and export across various global markets.
In a statement on Thursday, Biological E said it has entered into an agreement with Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical firms of Johnson & Johnson, “for drug substance and drug product for Johnson & Johnson’s COVID-19 vaccine candidate, Ad26.COV2.S.”
Biological E Managing Director Mahima Datla said “Given the magnitude of the COVID-19 pandemic, our ability to mount an effective response will be predicated on the ability to supply the vaccine globally and in significant quantities. This is best achieved through collaboration.”
Making it clear that BE will continue clinical trials on its own Covid-19 vaccine candidate, she told ET that the production capacities of Biological E’s own vaccine candidate will be “between 50-80 million doses a month.”
Mahima refused to divulge the commercial terms Biological E entered into with J&J or the capacities of J&J to produce the vaccine in India.
Narender Dev Mantena, Director of BioE Holdings Inc., who heads Biological E’s novel vaccine initiative, said, “We look forward to deploying our manufacturing infrastructure to support Johnson & Johnson’s commitment to global access for its COVID-19 vaccine.”
The Hyderabad headquartered vaccine maker said in the recent years it has embarked on new initiatives for organisational expansion such as developing generic injectable products for regulated markets, exploring synthetic biology and metabolic engineering as a means to manufacture active pharmaceutical ingredients sustainably and developing novel vaccines for global use.